Cargando…
Covaxin: An overview of its immunogenicity and safety trials in India
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global coronavirus disease-19 (COVID-19) pandemic. Several vaccine types, such as inactivated, viral vector-, or mRNA-based, have received approval against SARS-CoV-2. The ability to induceT-helper-1 cell (Th1) r...
Autores principales: | Sharma, Rohit, Tiwari, Swati, Dixit, Aparna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070630/ https://www.ncbi.nlm.nih.gov/pubmed/35574502 http://dx.doi.org/10.6026/97320630017840 |
Ejemplares similares
-
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022) -
“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021) -
Covaxin-Induced Lymphocytic Myocarditis
por: Mittal, Nitish, et al.
Publicado: (2022) -
Effectiveness of Covid-19 vaccines (Covishield(TM) and Covaxin (®)) in healthcare workers in Mumbai, India: A retrospective cohort analysis
por: Contractor, Aashish, et al.
Publicado: (2022) -
Herpes Zoster Following Covaxin Receipt
por: Muhie, Oumer Abdu, et al.
Publicado: (2021)